A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells

Medical Oncology
Jingrui JinJie Jin

Abstract

Acute myeloid leukemia (AML) is a devastating disease. Hybrid agents with dual activity, which have been shown to possess anti-cancer effect, are expected to potentially improve the prognosis of AML patients. EDO-S101 is a novel alkylating deacetylase inhibitor molecule synthesized by the addition of the hydroxamic acid of histone deacetylases inhibitor vorinostat into bendamustine, a DNA-damaging agent. However, the effect of EDO-S101 in combination with traditional chemotherapy drugs has not been studied in AML. In this study, we investigated the effect of EDO-S101 in combination with cytarabine in treating AML cells. The synergic activity against AML was identified by remarkable reduction of cell viability, significant apoptosis enhancement and the upregulation of the cleaved PARP, Casepase-3 and -7 proteins compared with monotherapy. To explain the drivers, we detected the DNA damage pathway including DNA double-strand breaks marker γ-H2AX and DNA damage checkpoint proteins, which was supposed to be responsible for the enhanced apoptosis activity. In summary, our data demonstrated that EDO-S101 in combination with cytarabine could synergistically induce the apoptosis of AML cells and it might be a potential regimen for trea...Continue Reading

References

May 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·P P MajorD W Kufe
Oct 24, 1997·Advances in Cancer Research·S Grant
Dec 2, 2000·Nature·B B Zhou, S J Elledge
May 23, 2001·Drugs·J A Balfour, K L Goa
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·A Lopez-GironaP Russell
Feb 1, 2002·The Journal of Biological Chemistry·Ted O'NeillGary A Rathbun
Nov 26, 2002·Nature Cell Biology·Oscar Fernandez-CapetilloAndré Nussenzweig
Jun 7, 2003·Science·Lee Zou, Stephen J Elledge
Jul 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anupama MunshiRaymond E Meyn
Jan 19, 2007·Haematologica·Ugo Testa, Roberta Riccioni
Feb 3, 2007·Nature Reviews. Drug Discovery·Steven GrantPeter Kirkpatrick
Oct 10, 2008·Clinical Journal of Oncology Nursing·Susan BlumelNam H Dang
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Feb 13, 2013·Lancet·Felicetto Ferrara, Charles A Schiffer
Dec 19, 2015·Nature Reviews. Cancer·Wynand P RoosBernd Kaina
Jun 3, 2016·CA: a Cancer Journal for Clinicians·Kimberly D MillerAhmedin Jemal
Nov 23, 2017·Nature Communications·Alessandro Di TullioDominique Bonnet
Nov 14, 2018·Nature Genetics·Salam A AssiConstanze Bonifer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.